Santhera Pharmaceuticals Holding AG Company Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD).

Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.

Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding AG

Country	Switzerland
Founded	2004
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	45
CEO	Dario Eklund

Contact Details

Address: Hohenrainstrasse 24 Pratteln, 4133 Switzerland
Phone	41 61 906 89 50
Website	santhera.com

Stock Details

Ticker Symbol	0QN1
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH1276028821
SIC Code	2834

Key Executives

Name	Position
Dario Eklund	Chief Executive Officer
Dr. Thomas Meier Ph.D.	Founder and Chairman
Andrew P. Smith CGMA, FCMA	Chief Financial Officer
Oliver Strub	Head of Compliance
Shabir Hasham M.D.	Chief Medical Officer
Marc Schrader	Chief Technology Officer
Dr. Oliver P. Kronenberg	Chief Legal Officer and Corporate Secretary
Neville Kodkani M.D.	Head of Global Marketing and Partner Management
Sarah Holmes-Klotz	Head of People and Culture
Andreas Missy	Executive Vice President of Corporate Planning and Business Development